Share Email Print

Proceedings Paper

Photodynamic therapy for treatment subretinal neovascularization
Author(s): Sergey E. Avetisov; Maria V. Budzinskaja; Tatyana N. Kiseleva; Natalia V. Balatskaya; Irina V. Gurova; Viktor B. Loschenov; Sergey A. Shevchik; Sergey G. Kuzmin; Georgy N. Vorozhtsov
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

This work are devoted our experience with photodynamic therapy (PDT) with <<Photosens>> for patients with choroidal neovascularization (CNV). 18 patients with subfoveal CNV in age-related macular degeneration (AMD), 24 patients with subfoveal CNV in pathological myopia (PM) and 4 patients with subfoveal CNV associated with toxoplasmic retinochoroiditis were observed. CNV was 100% classic in all study patients. Standardized protocol refraction, visual acuity testing, ophthalmologic examinations, biomicroscopy, fluorescein angiography, and ultrasonography were performed before treatment and 1 month, 3 months, 6 months, and 1 year after treatment; were used to evaluate the results of photodynamic therapy with <<Photosens>> (0.02% solution of mixture sulfonated aluminium phtalocyanine 0.05 mg/kg, intravenously). A diode laser (<<Biospec>>, Inc, Moscow) was used operating in the range of 675 nm. Need for retreatment was based on fluorescein angiographic evidence of leakage at 3-month follow-up intervals. At 3, 6, 9 month 26 (56.5%) patients had significant improvement in the mean visual acuity. At the end of the 12-month minimal fluorescein leakage from choroidal neovascularization was seen in 12 (26.1%) patients and the mean visual acuity was slightly worse than 0.2 which was not statistically significant as compared with the baseline visual acuity. Patients with fluorescein leakage from CNV underwent repeated PDT with <<Photosens>>. 3D-mode ultrasound shown the decreasing thickness of chorioretinal complex in CNV area. Photodynamic therapy with <<Photosens>> can safely reduce the risk of severe vision loss in patients with predominantly classic subfoveal choroidal neovascularization secondary to AMD, PM and toxoplasmic retinochoroiditis.

Paper Details

Date Published: 13 July 2007
PDF: 6 pages
Proc. SPIE 6632, Therapeutic Laser Applications and Laser-Tissue Interactions III, 663212 (13 July 2007); doi: 10.1117/12.730392
Show Author Affiliations
Sergey E. Avetisov, Eye Disease Research Institute (Russia)
Maria V. Budzinskaja, Eye Disease Research Institute (Russia)
Tatyana N. Kiseleva, Eye Disease Research Institute (Russia)
Natalia V. Balatskaya, SUE ISCC Intermedbiophyschim (Russia)
Irina V. Gurova, Eye Disease Research Institute (Russia)
Viktor B. Loschenov, General Physics Institute (Russia)
Sergey A. Shevchik, General Physics Institute (Russia)
Sergey G. Kuzmin, SUE ISCC Intermedbiophyschim (Russia)
Georgy N. Vorozhtsov, SUE ISCC Intermedbiophyschim (Russia)

Published in SPIE Proceedings Vol. 6632:
Therapeutic Laser Applications and Laser-Tissue Interactions III
Alfred Vogel, Editor(s)

© SPIE. Terms of Use
Back to Top